Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · IEX Real-Time Price · USD
5.93
+0.26 (4.59%)
May 2, 2024, 1:39 PM EDT - Market open
Wave Life Sciences Revenue
In the year 2023, Wave Life Sciences had annual revenue of $113.31M with 3,005.10% growth. Revenue in the quarter ending December 31, 2023 was $29.06M with 2,245.12% year-over-year growth.
Revenue (ttm)
$113.31M
Revenue Growth
+3,005.10%
P/S Ratio
6.15
Revenue / Employee
$425,959
Employees
266
Market Cap
726.57M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
Dec 31, 2017 | 3.89M | 2.80M | 256.50% |
Dec 31, 2016 | 1.09M | 940.00K | 618.42% |
Dec 31, 2015 | 152.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Pennant Group | 544.89M |
Treace Medical Concepts | 187.12M |
SIGA Technologies | 139.92M |
Mobile-health Network Solutions | 7.87M |
Dianthus Therapeutics | 2.83M |
Autolus Therapeutics | 1.70M |
WVE News
- 5 hours ago - Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 - GlobeNewsWire
- 2 days ago - Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 9 days ago - Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing - GlobeNewsWire
- 5 weeks ago - Wave Life Sciences to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024 - GlobeNewsWire
- 2 months ago - Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 months ago - Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones - GlobeNewsWire